INCYTE CORPORATION Equity Securities, FV-NI, Gain (Loss)
INCYTE CORPORATION (INCY) reported Equity Securities, FV-NI, Gain (Loss) of $6.59 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2026-04-28
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for the quarter ending 2026-03-31 was $6.59M.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for the quarter ending 2025-12-31 was $18.25M.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for the quarter ending 2025-09-30 was $8.56M.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for the quarter ending 2025-06-30 was -$4.15M, a 110.58% decline year-over-year.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for fiscal 2025 was $21.31M, a 81.63% decline from fiscal 2024.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for fiscal 2024 was $116.03M, a 164.34% increase from fiscal 2023.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for fiscal 2023 was $43.89M.
- INCYTE CORPORATION equity securities, fv-ni, gain (loss) for fiscal 2022 was -$87.59M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 3 month | Equity Securities, FV-NI, Gain (Loss) 6 month | Equity Securities, FV-NI, Gain (Loss) 9 month | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | $6.59M 10-Q · filed 2026-04-28 | $24.84M derived: sum of 2 quarters · filed 2026-04-28 | $33.40M derived: sum of 3 quarters · filed 2026-04-28 | $29.24M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | $18.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $26.80M derived: sum of 2 quarters · filed 2026-02-10 | $22.65M derived: sum of 3 quarters · filed 2026-02-10 | $21.31M 10-K · filed 2026-02-10 |
| 2025-09-30 | $8.56M 10-Q · filed 2025-10-28 | $4.41M derived: sum of 2 quarters · filed 2025-10-28 | $3.06M 10-Q · filed 2025-10-28 | -$7.12M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-06-30 | -$4.15M 10-Q · filed 2025-07-29 | -$5.49M 10-Q · filed 2025-07-29 | -$15.68M derived: sum of 3 quarters · filed 2026-04-28 | -$28.66M derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-03-31 | -$1.34M 10-Q · filed 2026-04-28 | -$11.52M derived: sum of 2 quarters · filed 2026-04-28 | -$24.51M derived: sum of 3 quarters · filed 2026-04-28 | $14.73M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$23.16M derived: sum of 2 quarters · filed 2026-02-10 | $16.08M derived: sum of 3 quarters · filed 2026-02-10 | $116.03M 10-K · filed 2026-02-10 |
| 2024-09-30 | -$12.98M 10-Q · filed 2025-10-28 | $26.26M derived: sum of 2 quarters · filed 2025-10-28 | $126.21M 10-Q · filed 2025-10-28 | $160.26M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $39.24M 10-Q · filed 2025-07-29 | $139.19M 10-Q · filed 2025-07-29 | $173.24M derived: sum of 3 quarters · filed 2026-02-10 | $146.59M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $99.95M 10-Q · filed 2025-04-29 | $134.00M derived: sum of 2 quarters · filed 2026-02-10 | $107.35M derived: sum of 3 quarters · filed 2026-02-10 | $149.16M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $7.40M derived: sum of 2 quarters · filed 2026-02-10 | $49.21M derived: sum of 3 quarters · filed 2026-02-10 | $43.89M 10-K · filed 2026-02-10 |
| 2023-09-30 | -$26.65M 10-Q · filed 2024-10-29 | $15.16M derived: sum of 2 quarters · filed 2024-10-29 | $9.84M 10-Q · filed 2024-10-29 | |
| 2023-06-30 | $41.81M 10-Q · filed 2024-07-30 | $36.49M 10-Q · filed 2024-07-30 | ||
| 2022-12-31 | -$87.59M 10-K · filed 2025-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |